Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 3, 2014, Pages 470-479

  Hayashi, Shusaku ^a,c   Kurata, Naoto ^a   Yamaguchi, Aya ^a   Amagase, Kikuko ^a   Takeuchi, Koji ^a,b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b General Incorporated Association Kyoto Research Center for Gastrointestinal Diseases   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LUBIPROSTONE; MESSENGER RNA; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; INTESTINAL DYSMOTILITY; INTESTINE INJURY; MALE; MEDIATOR RELEASE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; RAT; SECRETION (PROCESS); STOMACH PROTECTION; UPREGULATION;

ALPROSTADIL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; NAPHTHALENES; NITRIC OXIDE SYNTHASE TYPE II; PHENYLBUTYRATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901242603     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213991     Document Type: Article

References (44)

1. Aihara E, Nomura Y, Sasaki Y, Ise F, Kita K, and Takeuchi K (2007) Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci 80:2446-2453.
2. 2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. J Gastroenterol Hepatol 25 (Suppl 1):S111-S118.
3. Bao HF, Liu L, Self J, Duke BJ, Ueno R, and Eaton DC (2008) A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol 295:G234-G251.
4. Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, Lee K, and Sanger GJ (2008) Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 154:126-135.
5. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chaussade S, and Chauvelot-Moachon L (1998) Increase in tumor necrosis factor-Alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 124:1385-1394.
6. -secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 137:976-985.
7. Boughton-Smith NK, Evans SM, Laszlo F, Whittle BJ, and Moncada S (1993) The induction of nitric oxide synthase and intestinal vascular permeability by endo-toxin in the rat. Br J Pharmacol 110:1189-1195.
8. Calignano A, Whittle BJ, Di Rosa M, and Moncada S (1992) Involvement of endogenous nitric oxide in the regulation of rat intestinal motility in vivo. Eur J Pharmacol 229:273-276.
9. Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML, and Ueno R (2004) SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 287:C1173-C1183.
10. Cuthbert AW (2011) Lubiprostone targets prostanoid EP4 receptors in ovine airways. Br J Pharmacol 162:508-520.
11. Deitch EA, Ma L, Ma WJ, Grisham MB, Granger DN, Specian RD, and Berg RD (1989) Inhibition of endotoxin-induced bacterial translocation in mice. J Clin Invest 84:36-42.
12. Fang WF, Broughton A, and Jacobson ED (1977) Indomethacin-induced intestinal inflammation. Am J Dig Dis 22:749-760.
13. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, and Sakamoto C (2009) Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 69: 1339-1346.
14. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, and Fort JG (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3:133-141.
15. Hatazawa R, Ohno R, Tanigami M, Tanaka A, and Takeuchi K (2006) Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. J Pharmacol Exp Ther 318:691-699.
16. Hayashi S, Kurata N, Kitahirachi E, Nishimura Y, Amagase K, Yano T, and Takeuchi K (2013) Cinacalcet, a calcimimetic, prevents nonsteroidal antiin-flammatory drug-induced small intestinal damage in rats. J Physiol Pharmacol 64: 453-463.
17. Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, and Takeuchi K (2008) Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 53:2657-2666.
18. Kato S, Tanaka A, Kunikata T, Umeda M, and Takeuchi K (2000) Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons. Digestion 61:39-46.
19. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 47:894-904.
20. Kunikata T, Miyazawa T, Kanatsu K, Kato S, and Takeuchi K (2002b) Protective effect of thiaton, an antispasmodic drug, against indomethacin-induced intestinal damage in rats. Jpn J Pharmacol 88:45-54.
21. Krawisz JE, Sharon P, and Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344-1350.
22. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, and Bjarnason I (2005) A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128:1172-1178.
23. Mizumori M, Akiba Y, and Kaunitz JD (2009) Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 54:2063-2069.
24. Norimatsu Y, Moran AR, and MacDonald KD (2012) Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun 426:374-379.
25. Robert A, Nezamis JE, Lancaster C, Hanchar AJ, and Klepper MS (1976) Enter-opooling assay: a test for diarrhea produced by prostaglandins. Prostaglandins 11: 809-828.
26. Robert A and Asano T (1977) Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14:333-341.
27. Satoh H, Amagase K, and Takeuchi K (2012) Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 343:270-277.
28. Satoh H, Amagase K, and Takeuchi K (2014) Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats. J Pharmacol Exp Ther 348:227-235.
29. Schey R and Rao SS (2011) Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 56:1619-1625.
30. Schwiebert EM, Cid-Soto LP, Stafford D, Carter M, Blaisdell CJ, Zeitlin PL, Guggino WB, and Cutting GR (1998) Analysis of ClC-2 channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells. Proc Natl Acad Sci USA 95: 3879-3884.
31. Tanaka A, Kunikata T, Mizoguchi H, Kato S, and Takeuchi K (1999) Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol 50:405-417.
32. Tanaka A, Hase S, Miyazawa T, and Takeuchi K (2002) Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300:754-761.
33. Takeuchi K, Ueki S, and Okabe S (1986) Importance of gastric motility in the patho-genesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci 31:1114-1122.
34. Takeuchi K, Miyazawa T, Tanaka A, Kato S, and Kunikata T (2002a) Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 66:30-41.
35. Takeuchi K, Ogawa Y, Kawagawa S, and Ukawa H (2002b) Gastric ulcerogenic responses following barrier disruption in knockout mice lacking prostaglandin EP1 receptors. Aliment Pharmacol Ther 16:74-82 DOI: 10.1046/j.1365-2036.16. s2.21.x.
36. Takeuchi K, Yokota A, Tanaka A, and Takahira Y (2006) Factors involved in upre-gulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 51:1250-1259.
37. Takeuchi K, Tanaka A, Kato S, Aihara E, and Amagase K (2007) Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther 322:903-912.
38. Takeuchi K, Tanaka A, Kato S, Amagase K, and Satoh H (2010a) Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 411:459-466.
39. 2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression via activation of EP4 receptors. J Gastroenterol Hepatol 25 (Suppl 1):S67-S74.
40. Takeuchi K, Kita K, Hayashi S, and Aihara E (2011) Regulatory mechanism of duodenal bicarbonate secretion: Roles of endogenous prostaglandins and nitric oxide. Pharmacol Ther 130:59-70.
41. 2 on NSAID-induced small intestinal damage, in Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment (Filaretova LP and Takeuchi K, eds) pp 41-51, Karger, Basel.
42. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, and Collins SM, et al. (2011) Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141:1314-1322, e1-e5.
43. Whittle BJ (1981) Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94-98.
44. Woodward DF, Jones RL, and Narumiya S (2011) International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63:471-538.